Company: DVAX
Filing Date: 2025-08-21
Form Type: 8-K
Source: 0001193125-25-184680
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-21
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On August 21, 2025, Dynavax Technologies Corporation (“ Dynavax” or the “ Company”) issued a press release announcing topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, the Company’s novel shingles vaccine candidate, head-to-headversus Shingrix in participants aged 50 to 69 years. The Company has also updated its corporate presentation to include information regarding the Phase 1/2 clinical trial. Copies of the press release and the presentation are attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form8-K, respectively.

All of the information furnished in this Current Report on Form8-K, including the accompanying Exhibits, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Current Report on Form8-Kand in the accompanying exhibits shall not be incorporated by reference into any filing with the U. S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.